Scope of the Report
The report titled “Global PD-1 and PD-L1 Inhibitors Market: Size, Trends and Forecasts (2018-2022)”, provides an in depth analysis of the global PD-1 and PD-L1 inhibitors market by value, by cancer, by treatment, by region, etc. The report also provides a detailed analysis of the China PD-1 and PD-L1 inhibitors market by value, by treatment and by cancer.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global PD-1 and PD-L1 Inhibitors market has also been forecasted for the period 2018-2022, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The global PD-1 and PD-L1 inhibitors market is generally dominated. Many competitors have established worldwide reputation with the multinational patients while some provide their drugs to the domestic patients. The manufacturers of the PD-1 and PD-1 inhibitors market produce different type of drugs, some manufacturers produce PD-1 inhibitors, some produce PD-L1 inhibitors while other produce combination of PD-1 and PD-L1 inhibitors.

However, the competition in the global PD-1 and PD-L1 inhibitors market is dominated by few PD-1 and PD-L1 inhibitors manufacturers. Further, key players of the PD-1 and PD-L1 inhibitors market are Bristol-Myers Squibb, Merck & Co., Inc., Roche, AstraZeneca, Jiangsu Hengrui Medicine Co. Ltd. and BeiGene, Ltd. are also profiled with their financial information and respective business strategies.

Country Coverage

  • China
  • The US
  • ROW

Company Coverage

  • Bristol-Myers Squibb
  • Merck & Co., Inc.
  • Roche
  • AstraZeneca
  • Jiangsu Hengrui Medicine Co. Ltd.
  • BeiGene, Ltd.

Executive Summary
Cancer is the fastest growing disease across the world and one of the most important development in the field of cancer treatment is the introduction of immune checkpoint inhibitors-agents that help to stimulate the immune system. The two main cancer treatment approaches are: Programmed Death-1 (PD-1) and Programmed Death Ligand-1 (PD-L1) inhibitors. PD-1 and PD-L1 inhibitors are both found on the surface of the cancer cells and used to kill cancer cells.

The drugs approved as a PD-1 inhibitor are Pembrolizumab and Nivolumab and the drugs approved as a PD-L1 inhibitors are atezolizumab, Durvalumab and Avelumab. There are various PD-1 and PD-L1 inhibitors which are still in experimental phase of development. The adverse effects of PD-1 and PD-L1 inhibitors are pneumonitis, colitis, skin reactions, immune thrombocytopenia, cardiac insufficiency, diarrhea, pruritus, myocarditis and pneumonitis. PD-1 and PD-L1 inhibitors has a long history with continuously evolving new generation PD-1 and PD-L1 inhibitors. The PD-1 and PD-L1 inhibitors market can be segmented on the basis of type, indications, drug and distribution channel.

The global PD-1 and PD-L1 inhibitors market has increased at a significant annual growth rate during the years 2016-2017 and projections are made that the market would rise in the next four years i.e. 2018-2022 tremendously. The PD-1 and PD-L1 inhibitors market is expected to increase due to aging population, growth in GNI per capita, growing urban population, increasing incidence of certain types of cancer, rise in the number of people with cancer, etc. Yet the market faces some challenges such as high cost of oncology treatment, side effects and toxicity, failure of clinical trials, time consuming and uncertain regulatory process, etc.